Congenica Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 70
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $7.62M
Latest Deal Amount
  • Investors
  • 11

Congenica General Information

Description

Developer of a clinical genome interpretation technology designed to identify genetic diseases in patients. The company's medical technology processes genomic datasets to detect mutations by filtering clinically relevant variants and deep clinical phenotyping, enabling clinicians and researchers to interrogate the human genome to identify disease-causing variants.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Outcome Management (Healthcare)
Biotechnology
Primary Office
  • Wellcome Genome Campus
  • Cambridge CB10 1DR
  • England, United Kingdom
+44 01223 000000

Congenica Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Congenica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 28-Sep-2020 $7.62M 000.00 000.00 Completed Generating Revenue
7. Later Stage VC (Series B) 30-Apr-2019 000.00 000.00 000.00 Completed Generating Revenue
6. Grant 29-Sep-2015 00000 00.000 Completed Generating Revenue
5. Early Stage VC (Series A) 01-Apr-2015 00.000 00.000 00.00 Completed Generating Revenue
4. Grant 11-Mar-2015 00.000 00.000 Completed Startup
3. Seed Round 05-Dec-2014 00.000 00.000 Completed Startup
2. Seed Round 01-Oct-2014 $814K $814K 00.000 Completed Startup
1. Grant 02-May-2014 $570K Completed Startup
To view Congenica’s complete valuation and funding history, request access »

Congenica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
B Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
B Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 4,396,070 $0.001299 $0.65 $0.65 1x $0.65 12.23%
A Ordinary 2,553,500 $0.001299 $0.25 $0.25 1x $0.25 7.1%
To view Congenica’s complete cap table history, request access »

Congenica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a clinical genome interpretation technology designed to identify genetic diseases in patients. The company'
Decision/Risk Analysis
Cambridge, United Kingdom
70 As of 2020
000.00
00.00 0000-00-00
0000000000 0 000.00

0000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000000000000 00000000
Boston, MA
000 As of 0000
00000
00000000000 00000

000000 0

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000000 00000000
San Francisco, CA
0 As of 0000
00.00
000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Congenica Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genuity Science Venture Capital-Backed Boston, MA 000 00000 00000000000 00000
000000 00000000 Venture Capital-Backed San Francisco, CA 0 00.00 000000000 00.00
000000000 Venture Capital-Backed Ann Arbor, MI 0 000.00 0000000000 0 000.00
0000000000 (000000 Venture Capital-Backed New York, NY 00 000.00 00000000000 000.00
00000000 00000000 Formerly VC-backed San Jose, CA 000 00000 000000&0 00000
You’re viewing 5 of 29 competitors. Get the full list »

Congenica Executive Team (17)

Name Title Board Seat Contact Info
David Atkins Ph.D Chief Executive Officer & Board Member
Wendy Britten Chief Financial Officer
Nicholas Lench Ph.D Co-Founder, Chief Operating Officer, Chief Scientific Officer & Board Member
Peter Fox Chief Technology Officer
Rob Denison Chief Information Officer
You’re viewing 5 of 17 executive team members. Get the full list »

Congenica Board Members (17)

Name Representing Role Since
Alastair Kilgour Parkwalk Advisors Board Member 000 0000
Andrew Richards Ph.D Congenica Chairman 000 0000
David Atkins Ph.D Congenica Chief Executive Officer & Board Member 000 0000
Heiner Dreismann Ph.D Self Board Member 000 0000
Matthew Hurles Ph.D Congenica Co-Founder, Scientific Director & Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Congenica Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Congenica Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BGI Corporation Minority 000 0000 000000 0
Bioscience Managers Venture Capital Minority 000 0000 000000 0
Digital China Health PE-Backed Company Minority 000 0000 000000 0
Future Planet Capital Growth/Expansion Minority 000 0000 000000 0
Healthlink Capital Other Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »